Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD
Rhea-AI Summary
Outlook Therapeutics (Nasdaq: OTLK) announced FDA acceptance of its resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) to treat neovascular age-related macular degeneration (wet AMD).
The resubmission is under a Class 1 review with a Prescription Drug User Fee Act (PDUFA) target action date of July 29, 2026. Outlook Therapeutics has begun pre-launch activities while the FDA review proceeds.
Positive
- FDA accepts resubmitted BLA for ONS-5010/LYTENAVA™ in wet AMD
- Class 1 FDA review with PDUFA target action date July 29, 2026
- Company initiates pre-launch activities ahead of potential ONS-5010 approval
- If approved, product expected to be first FDA-approved ophthalmic bevacizumab formulation
Negative
- Regulatory approval for ONS-5010/LYTENAVA™ remains pending with no FDA decision yet
News Market Reaction – OTLK
In the Jun 16 session, OTLK gained 35.34%, reflecting a significant positive market reaction. Argus tracked a peak move of +40.5% during that session. Our momentum scanner triggered 63 alerts that day, indicating high trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 01 | BLA resubmission | Positive | +15.5% | FDA BLA resubmission for ONS-5010 with no additional trials required. |
| May 28 | Equity offering | Negative | -1.4% | Registered direct offering of $5.0M to largest shareholder at market pricing. |
| May 26 | FDA appeal win | Positive | +29.1% | FDA Office of New Drugs grants appeal, supports Class 1 BLA resubmission. |
| May 15 | Earnings update | Neutral | +0.5% | Q2 FY2026 results and updates on EU commercialization and FDA dispute process. |
| Apr 23 | Equity financing | Negative | +9.8% | Closing of $5.0M registered direct offering with new warrants at $0.31. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows strong positive reactions to regulatory progress on ONS-5010/LYTENAVA™, while capital-raising events have produced smaller or even divergent price moves.
Over the past few months, Outlook Therapeutics has advanced ONS-5010/LYTENAVA™ toward potential U.S. approval, with the FDA appeal win on May 26, 2026 and BLA resubmission on June 1, 2026 driving gains of 29.14% and 15.48%, respectively. Financing steps in April and May 2026 raised about $5.0M each via registered direct offerings, while Q2 FY2026 results highlighted a reduced net loss of $4.5M and cash of $7.7M. Today’s acceptance of the resubmitted BLA fits this ongoing regulatory narrative.
Key Terms
prescription drug user fee act (pdufa) regulatory
pdufa regulatory
biologics license application (bla) regulatory
biologics license application regulatory
bevacizumab-vikg medical
wet amd medical
pharmacovigilance medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Prescription Drug User Fee Act (PDUFA) goal date of July 29, 2026
ISELIN, N.J., June 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ for the treatment of neovascular age-related macular degeneration (nAMD), or wet AMD. The Company has been informed that the resubmission is a Class 1 review, with a PDUFA target action date of July 29, 2026.
“We are very pleased that the FDA has accepted our resubmitted BLA to review the labelling as part of the final step toward potential approval,” said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. “This is great news for Outlook and the LYTENAVA™ team, patients and the retina community. We look forward to collaborating with the FDA over the coming weeks. We are incredibly grateful to our teams, partners, and KOLs for their resilience and dedication.”
When approved, ONS-5010/LYTENAVA™ will be the first and only FDA-approved ophthalmic formulation of bevacizumab supported by standardized manufacturing, FDA-approved labeling, and robust pharmacovigilance. Outlook Therapeutics has initiated pre-launch activities in anticipation of the pending BLA approval.
About ONS-5010 / LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma)
ONS-5010/LYTENAVA™ is an ophthalmic formulation of bevacizumab produced in the United States for the treatment of wet AMD. LYTENAVA™ (bevacizumab gamma) is the subject of a centralized Marketing Authorization granted by the European Commission in the EU and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the treatment of wet AMD. In certain European Union Member States, ONS-5010/LYTENAVA™ must receive pricing and reimbursement approval before it can be sold.
In the United States, ONS-5010/LYTENAVA ™ (bevacizumab-vikg) is investigational. When approved, it will be the first ophthalmic formulation approved by the FDA.
Bevacizumab-vikg (bevacizumab gamma in the EU and UK) is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. Following intravitreal injection, the binding of bevacizumab to VEGF prevents the interaction of VEGF with its receptors on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation in the retina.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma). LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany, Austria, and the UK as a treatment for wet AMD.
Forward-Looking Statements
This press release contains statements that may or are considered “forward-looking statements”. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “can,” “potential,” “target,” when, or “would”, the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, plans for continued engagement with the FDA and the potential to agree on a regulatory pathway for ONS-5010, the potential of ONS-5010/LYTENAVA™ as a treatment for wet AMD, the potential for ONS-5010 to receive approval from the FDA, and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties, and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing and commercializing pharmaceutical product candidates, risks in obtaining necessary regulatory approvals, the content and timing of decisions by regulatory bodies, as well as those risks detailed in Outlook Therapeutics’ filings with the Securities and Exchange Commission (the SEC), including its Annual Report on Form 10-K for the fiscal year ended September 30, 2025, filed with the SEC on December 19, 2025, as updated by the Outlook Therapeutics’ subsequent filings, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of global geopolitical conflict, tariffs and trade tensions, fluctuations in interest rates and inflation, and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend, or clarify these forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities law.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com
